Aminolevulinic Acid-Photodynamic Therapy Combined with Topically Applied Vascular Disrupting Agent Vadimezan Leads to Enhanced Antitumor Responses

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

(2010) R. Pili et al.   CLINICAL CANCER RESEARCH

Recent advances in the prevention and treatment of skin cancer using photodynamic therapy

(2010) Baozhong Zhao et al.   Expert Review of Anticancer Therapy

Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: a case report

(2010) Ulas Sunar et al.   OPTICS EXPRESS

Taking treatment decisions in non-melanoma skin cancer—The place for topical photodynamic therapy (PDT)

(2010) A. Sidoroff et al.   Photodiagnosis and Photodynamic Therapy

Monitoring blood flow responses during topical ALA-PDT

(2010) Theresa L. Becker et al.   Biomedical Optics Express

Simulations of measured photobleaching kinetics in human basal cell carcinomas suggest blood flow reductions during ALA-PDT

(2009) Ken Kang-Hsin Wang et al.   LASERS IN SURGERY AND MEDICINE

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

(2009) Mark J. McKeage et al.   LUNG CANCER

An overview of topical photodynamic therapy in dermatology

(2009) Sally H. Ibbotson   Photodiagnosis and Photodynamic Therapy

Guidelines for topical photodynamic therapy: update

(2008) C.A. Morton et al.   BRITISH JOURNAL OF DERMATOLOGY

Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial

(2008) K. Mosterd et al.   BRITISH JOURNAL OF DERMATOLOGY

Irradiance-Dependent Photobleaching and Pain in  -Aminolevulinic Acid-Photodynamic Therapy of Superficial Basal Cell Carcinomas

(2008) W. J. Cottrell et al.   CLINICAL CANCER RESEARCH

Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevulinate

(2008) Henriëtte S. de Bruijn et al.   JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY

The Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Improves the Antitumor Efficacy and Shortens Treatment Time Associated with Photochlor-sensitized Photodynamic TherapyIn Vivo

(2008) Mukund Seshadri et al.   PHOTOCHEMISTRY AND PHOTOBIOLOGY